Cognition Therapeutics Inc. has reported a net loss of $6.7 million for the second quarter ended June 30, 2025, compared to a net loss of $7.0 million for the same period in 2024. The company's cash, cash equivalents, and restricted cash equivalents were approximately $11.6 million as of June 30, 2025. Additionally, Cognition Therapeutics has $41.9 million in total obligated grant funds remaining from the National Institute of Aging. Research and development expenses for the quarter were $11.5 million, a slight decrease from $11.6 million in the comparable period of 2024, primarily due to reduced professional fees. General and administrative expenses also decreased to $2.5 million from $3.1 million in the previous year, driven mainly by reduced stock-based compensation expenses. The company highlighted significant progress in its clinical programs, including a productive end-of-phase 2 meeting with the FDA for its Alzheimer's disease program and the initiation of an expanded access program for people with dementia with Lewy bodies. Cognition also surpassed 50% enrollment in its Phase 2 'START' study of zervimesine for early Alzheimer's disease. These advancements emphasize the potential of zervimesine to slow the progression of age-related degenerative diseases. The company estimates that its current cash resources will fund operations and capital expenditures into the second quarter of 2026.